Cisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It
remains an important and effective therapy in many forms of cancer today. Cisplatin …

Cisplatin is a widely used and highly effective cancer chemotherapeutic agent. One of the
limiting side effects of cisplatin use is nephrotoxicity. Research over the past 10 years has …

Medications are a common cause of AKI, especially for patients admitted to hospital wards
and the intensive care unit. Although drug-related kidney injury occurs through different …

Since the discovery of the biologically active platinum complexes 30 years ago, 2 agents
have become widely established in clinical oncology practice. Both cisplatin and carboplatin …

In the present study we describe the toxicity of weekly high-dose (70–85 mg m− 2) cisplatin
in 400 patients (203 men, 197 women; median age 54 years) with advanced solid tumours …

Despite available prevention and treatment measures, such as hydration, diuresis,
magnesium supplementation, and amifostine, renal toxicity is still one of the major dose …

A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients with
renal insufficiency. This manuscript outlines recommended dosing adjustments for cancer …

Abstract Purpose: NC-6004, a novel cisplatin nanoparticle developed using micellar
technology exhibits sustained release of cisplatin and selective distribution to tumors …

Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers. Despite
the potential for both severe acute and chronic side effects, it remains a preferred …

The frequent need to obtain an estimate of renal function in cancer patients, not least for
targeting carboplatin dose, has led to a number of approaches to estimate glomerular …